36378290|t|Novel proresolving lipid mediator mimetic 3-oxa-PD1n-3 docosapentaenoic acid reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin-2 in mice.
36378290|a|ABSTRACT: Specialized proresolving mediators (SPMs) have demonstrated potent analgesic actions in animal models of pathological pain. The actions of SPMs in acute and chronic itch are currently unknown. Recently, n-3 docosapentaenoic acid (DPA) was found to be a substrate for the biosynthesis of several novel families of SPMs and 3-oxa-PD1 n-3 DPA (3-oxa-PD1) is an oxidation-resistant metabolic stable analogue of the n-3 DPA-derived protectin D1 (PD1). In this article, we demonstrate that 3-oxa-PD1 effectively reduces both acute and chronic itch in mouse models. Intrathecal injection of 3-oxa-PD1 (100 ng) reduced acute itch induced by histamine, chloroquine, or morphine. Furthermore, intrathecal 3-oxa-PD1 effectively reduced chronic itch, induced by cutaneous T-cell lymphoma (CTCL), allergic contact dermatitis with dinitrofluorobenzene, and psoriasis by imiquimod. Intratumoral injection of 3-oxa-PD1 also suppressed CTCL-induced chronic itch. Strikingly, the antipruritic effect lasted for several weeks after 1-week intrathecal 3-oxa-PD1 treatment. Whole-cell recordings revealed significant increase in excitatory postsynaptic currents in spinal dorsal horn (SDH) neurons of CTCL mice, but this increase was blocked by 3-oxa-PD1. 3-oxa-PD1 further increased inhibitory postsynaptic currents in SDH neurons of CTCL mice. Cutaneous T-cell lymphoma increased the spinal levels of lipocalin-2 (LCN2), an itch mediator produced by astrocytes. 3-oxa-PD1 suppressed LCN2 production in CTCL mice and LCN2 secretion in astrocytes. Finally, CTCL-induced anxiety was alleviated by intrathecal 3-oxa-PD1. Our findings suggest that 3-oxa-PD1 potently inhibits acute and chronic itch through the regulation of excitatory or inhibitory synaptic transmission and astroglial LCN2 production. Therefore, stable SPM analogs such as 3-oxa-PD1 could be useful to treat pruritus associated with different skin injuries.
36378290	19	33	lipid mediator	Chemical	-
36378290	42	76	3-oxa-PD1n-3 docosapentaenoic acid	Chemical	-
36378290	103	107	itch	Disease	MESH:D011537
36378290	198	209	lipocalin-2	Gene	16819
36378290	213	217	mice	Species	10090
36378290	334	351	pathological pain	Disease	MESH:D010146
36378290	394	398	itch	Disease	MESH:D011537
36378290	432	457	n-3 docosapentaenoic acid	Chemical	-
36378290	459	462	DPA	Chemical	MESH:C026219
36378290	551	560	3-oxa-PD1	Chemical	-
36378290	561	568	n-3 DPA	Chemical	-
36378290	570	579	3-oxa-PD1	Chemical	-
36378290	640	647	n-3 DPA	Chemical	-
36378290	656	668	protectin D1	Chemical	MESH:C487679
36378290	670	673	PD1	Chemical	MESH:C487679
36378290	713	722	3-oxa-PD1	Chemical	-
36378290	766	770	itch	Disease	MESH:D011537
36378290	774	779	mouse	Species	10090
36378290	813	822	3-oxa-PD1	Chemical	-
36378290	846	850	itch	Disease	MESH:D011537
36378290	862	871	histamine	Chemical	MESH:D006632
36378290	873	884	chloroquine	Chemical	MESH:D002738
36378290	889	897	morphine	Chemical	MESH:D009020
36378290	924	933	3-oxa-PD1	Chemical	-
36378290	962	966	itch	Disease	MESH:D011537
36378290	979	1004	cutaneous T-cell lymphoma	Disease	MESH:D016410
36378290	1006	1010	CTCL	Disease	MESH:D016410
36378290	1013	1040	allergic contact dermatitis	Disease	MESH:D017449
36378290	1046	1066	dinitrofluorobenzene	Chemical	MESH:D004139
36378290	1072	1081	psoriasis	Disease	MESH:D011565
36378290	1085	1094	imiquimod	Chemical	MESH:D000077271
36378290	1122	1131	3-oxa-PD1	Chemical	-
36378290	1148	1152	CTCL	Disease	MESH:D016410
36378290	1169	1173	itch	Disease	MESH:D011537
36378290	1261	1270	3-oxa-PD1	Chemical	-
36378290	1409	1413	CTCL	Disease	MESH:D016410
36378290	1414	1418	mice	Species	10090
36378290	1453	1462	3-oxa-PD1	Chemical	-
36378290	1464	1473	3-oxa-PD1	Chemical	-
36378290	1543	1547	CTCL	Disease	MESH:D016410
36378290	1548	1552	mice	Species	10090
36378290	1554	1579	Cutaneous T-cell lymphoma	Disease	MESH:D016410
36378290	1611	1622	lipocalin-2	Gene	16819
36378290	1624	1628	LCN2	Gene	16819
36378290	1634	1638	itch	Disease	MESH:D011537
36378290	1672	1681	3-oxa-PD1	Chemical	-
36378290	1693	1697	LCN2	Gene	16819
36378290	1712	1716	CTCL	Disease	MESH:D016410
36378290	1717	1721	mice	Species	10090
36378290	1726	1730	LCN2	Gene	16819
36378290	1765	1769	CTCL	Disease	MESH:D016410
36378290	1778	1785	anxiety	Disease	MESH:D001007
36378290	1816	1825	3-oxa-PD1	Chemical	-
36378290	1853	1862	3-oxa-PD1	Chemical	-
36378290	1899	1903	itch	Disease	MESH:D011537
36378290	1992	1996	LCN2	Gene	16819
36378290	2027	2030	SPM	Chemical	-
36378290	2047	2056	3-oxa-PD1	Chemical	-
36378290	2082	2090	pruritus	Disease	MESH:D011537
36378290	2117	2130	skin injuries	Disease	MESH:D000069836
36378290	Positive_Correlation	MESH:D000077271	MESH:D011537
36378290	Association	MESH:D011537	16819
36378290	Positive_Correlation	MESH:D006632	MESH:D011537
36378290	Positive_Correlation	MESH:D002738	MESH:D011537
36378290	Positive_Correlation	MESH:D004139	MESH:D017449
36378290	Positive_Correlation	MESH:D009020	MESH:D011537
36378290	Positive_Correlation	MESH:D016410	16819
36378290	Association	MESH:D000077271	MESH:D011565
36378290	Positive_Correlation	MESH:D004139	MESH:D011537

